证券代码：605056 证券简称：咸亨国际 公告编号：2025-034 咸亨国际科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 本期业绩预告适用于实现盈利，且净利润与上年同期相比上升 50%以上 的情形。 ? 咸亨国际科技股份有限公司（以下简称"公司"）预计公司 2025 年半年 度实现归属于上市公司股东的净利润为 5,400 万元至 6,600 万元，比上年同期 （法 定披露数据）增加 1,145.07 万元至 2,345.07 万元，同比增加 27%至 55%。 ? 公司预计 2025 年半年度实现归属于上市公司股东的扣除非经常性损益 的净利润为 5,300 万元至 6,400 万元，比上年同期（法定披露数据）增加 1,178.12 万元至 2,278.12 万元，同比增加 29%至 55%。 （二） 业绩预告情况 股东的净利润为 5,400 万元至 6,600 万元，比上年同期（法定披露数据）增加 股东的扣除非经常性损益的净利润为 5,300 万元至 6,400 万元，比上年同期（法 ...

2025年7月8日 ， 瑞士医疗科技公司 Aktiia 宣布，其 G0无袖带血压监测系统 获得美国食品药品监督管理局（FDA）510(k)批准。 这是全球首款被批准可作为非处方 （OTC）产品上市的无袖带血压监测可穿戴设备，标志着血压管理从传统袖带向无创、连续、可穿戴技术的转折点。 G0系统计划于 2026年 在美国上市，初期将通过零售药店、电商和医疗渠道销售，预计售价在300美元左右。此前，该系统已 获得CE认证，并 在欧洲多个国家以 Hilo品牌销售。 # 无袖带血压监 测的 核心突破 Aktiia G0系统（美国市场称为Hilo Band），核心技术基于 光体积描记法（PPG） ，通过佩戴在手腕上的光学传感器，捕捉血管随心跳产生的微小体积变化，结合自 研的 CALFREE算法 ，实时估算收缩压（SBP）与舒张压（DBP）。 传统的血压监测依赖充气袖带，虽然精准，但存在几个痛点：测量过程需要主动操作，患者往往难以坚持；袖带反复充气造成不适，特别是夜间监测干扰睡眠；测 量频率低，可能漏掉血压波动。 G0系统针对这些问题，做出了以下技术突破： 虽然精度略低于传统袖带设备，但在连续性和用户体验方面，G0系统实现 ...

Raise your hand if you've ever scraped your knee or maybe cut your finger on a sharp object or maybe burned your hand on a hot stove. Most of us, right. Your body does something amazing.It sends in a repair team that lays down a scab to stop the bleeding and then specialized cells digest or remove all of that dead or injured tissue and lay down a scar. Now imagine this. What happens if your heart gets injured.Does it just scab over. Let me tell you a story where healing is more than just bandages. where glo ...

本报告导读： 公司深耕电力领域，拥有国家电网等能源领域的大型国央企客户，2024 年电力行业实现营收18.63 亿 元，贡献公司营收占比51.68%。 同时，凭借深耕电网领域经验优势，公司积极拓展至油气、发电、核工业、交通和政府应急等战略行 业，2024 年五大新战略行业实现营收约为10.91 亿元，同比增长约70.97%，实现高速增长。 公司作为MRO 集约化领先企业，紧抓国央企加速集约化和电商化采购的行业趋势，积极从电力行业向 油气、发电等重点战略行业拓展，业绩增长潜力巨大。 投资要点： 投资建议：作 为MRO集约化领先企业，公司立足电网行业向油气、发电等多个战略领域拓展，收入利 润体量有望持续增长。预计2025-2027 年EPS 分别为0.70、0.86、1.06 元，综合考虑不同估值方法并基 于谨慎性原则，我们给予公司2025 年4.08X PB，对应目标价为17.71 元，对应2025 年25.3X PE，首次覆 盖，给予增持评级。 中国MRO 市场成长潜力显著，集约化与数字化采购带来加速机遇。 MRO（Maintenance, Repair, and Operations）是指非主要生产设备和原 ...

FISCAL 2025 Q3 HIGHLIGHTS Net sales of $971.1 million decreased 0.8% YoY Operating income of $82.7 million, or $87.2 million on an adjusted basis1 Operating margin of 8.5%, or 9.0% on an adjusted basis1 Diluted EPS of $1.02 vs. $1.27 in the prior fiscal year quarter Adjusted diluted EPS of $1.08 vs. $1.33 in the prior fiscal year quarter1MELVILLE, N.Y. and DAVIDSON, N.C., July 1, 2025 /PRNewswire/ -- MSC INDUSTRIAL SUPPLY CO. (NYSE: MSM) ("MSC," "MSC Industrial," the "Company," "we," "us," or "our"), a lead ...

Analysts expect the Melville, New York-based company to report quarterly earnings at $1.03 per share, down from $1.33 per share in the year-ago period. MSC Industrial Direct projects to report quarterly revenue at $969.19 million, compared to $979.35 million a year earlier, according to data from Benzinga Pro. MSC Industrial, known for producing metalworking and maintenance, repair, and operations (MRO) products, reported a second-quarter net sales decline of 4.7% year-over-year to $891.7 million. It missed ...

Creating a Premier Energy and Industrial Solutions Provider June 26th, 2025 Disclaimers Forward-Looking Statements This presentation includes "forward-looking statements" as defined under the federal securities laws. All statements other than statements of historical fact included or incorporated by reference in this presentation, including, among other things, statements regarding the proposed business combination transaction between DNOW Inc. ("DNOW") and MRC Global Inc. ("MRC"), future events, plans and ...

Core Insights - Journey Medical Corporation will be included in the Russell 2000 and Russell 3000 Indexes effective after the close of U.S. equity markets on June 27, 2025, due to the 2025 annual Russell Index reconstitution [1][2] - The inclusion in these indexes is expected to enhance the company's visibility among investors and institutions [2] - Journey Medical's FDA-approved product, Emrosi™, for treating inflammatory lesions of rosacea, is experiencing a strong market entry, with plans to expand access and grow prescription volume [2] Company Overview - Journey Medical Corporation is a commercial-stage pharmaceutical company focused on marketing FDA-approved prescription products for dermatological conditions [6][7] - The company currently markets eight branded FDA-approved prescription drugs aimed at treating common skin conditions [6] - Founded by Fortress Biotech, Inc., Journey Medical is based in Scottsdale, Arizona [7] Market Context - The Russell 3000 Index includes the largest 3,000 U.S. public companies by market capitalization, while the Russell 2000 Index is a subset focused on small-cap companies [2] - Approximately $10.6 trillion in assets are benchmarked against Russell U.S. Indexes, which are widely utilized by investment managers and institutional investors [2]

Great Place to Work Certification™ reflects MSC's commitment to being an employer-of-choice.MELVILLE, N.Y. and DAVIDSON, N.C., June 16, 2025 /PRNewswire/ -- MSC INDUSTRIAL SUPPLY CO. (NYSE: MSM), a premier distributor of Metalworking and Maintenance, Repair and Operations supplies to industrial customers throughout North America, is proud to announce it has been Certified™ by Great Place To Work® for the second consecutive year in the United States, as well as in Canada, Mexico, and the United Kingdom for t ...

Core Viewpoint - ZKH Group Limited has announced a new share repurchase program, allowing the company to buy back up to US$50 million worth of its shares over the next 12 months, reflecting confidence in its intrinsic value and long-term growth prospects [1][3]. Company Overview - ZKH Group Limited is a leading maintenance, repair, and operations (MRO) procurement service platform in China, leveraging robust supply chain capabilities and innovative technology to serve a global customer base [4]. - The company operates through multiple online platforms, including the ZKH platform, GBB platform, and Northsky platform, providing tailored MRO procurement solutions aimed at reducing costs and improving management efficiency [4]. Financial Strategy - The share repurchase program will be funded from the company's existing cash balance, indicating a strong financial position [2]. - The program is expected to be executed through various means, including open market purchases and privately negotiated transactions, depending on market conditions [2]. Management Commentary - The Chairman and CEO of ZKH expressed strong confidence in the company's business model and its ability to drive sustainable growth, supported by a healthy balance sheet and effective strategic execution [3].